{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T12:21:05Z","timestamp":1761567665758,"version":"build-2065373602"},"reference-count":76,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013252","name":"TG Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013252","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Pharmacyclics"},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010293","name":"Seattle Genetics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010293","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","pet.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["PET Clinics"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.cpet.2019.03.008","type":"journal-article","created":{"date-parts":[[2019,4,12]],"date-time":"2019-04-12T17:36:55Z","timestamp":1555090615000},"page":"353-368","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Response-Adapted Treatment Strategies in Hodgkin Lymphoma Using PET Imaging"],"prefix":"10.1016","volume":"14","author":[{"given":"Steven M.","family":"Bair","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakub","family":"Svoboda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.cpet.2019.03.008_bib1","first-page":"7","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"10.1016\/j.cpet.2019.03.008_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clml.2018.03.012","article-title":"Immunotherapy for the treatment of Hodgkin lymphoma: an evolving paradigm","volume":"18","author":"Bair","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"10","key":"10.1016\/j.cpet.2019.03.008_bib4","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1172\/JCI61245","article-title":"Hodgkin lymphoma","volume":"122","author":"K\u00fcppers","year":"2012","journal-title":"J\u00a0Clin Invest"},{"issue":"17","key":"10.1016\/j.cpet.2019.03.008_bib5","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin\u00a0lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.cpet.2019.03.008_bib6","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.cpet.2019.03.008_bib7","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1182\/blood-2008-01-134783","article-title":"Aberrant expression of the Th2 cytokine IL-21 in Hodgkin lymphoma cells regulates STAT3 signaling and attracts Treg cells via regulation of MIP-3","volume":"112","author":"Lamprecht","year":"2008","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.cpet.2019.03.008_bib8","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/labinvest.2008.24","article-title":"The CD4+CD26\u2212 T-cell population in classical Hodgkin's lymphoma displays a distinctive regulatory T-cell profile","volume":"88","author":"Ma","year":"2008","journal-title":"Lab Invest"},{"issue":"7","key":"10.1016\/j.cpet.2019.03.008_bib9","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1182\/blood-2006-04-015164","article-title":"Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patients","volume":"108","author":"Gandhi","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.cpet.2019.03.008_bib10","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1046\/j.1365-2141.2000.02197.x","article-title":"Historical review of Hodgkin's disease","volume":"110","author":"Bonadonna","year":"2000","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.cpet.2019.03.008_bib11","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1001\/jama.1968.03140060016005","article-title":"Mechlorethamine HCl and cyclophosphamide in the treatment of Hodgkin's disease and the lymphomas","volume":"203","author":"Jacobs","year":"1968","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.cpet.2019.03.008_bib12","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1200\/JCO.2012.43.4803","article-title":"Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496)","volume":"31","author":"Gordon","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"9828","key":"10.1016\/j.cpet.2019.03.008_bib13","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/S0140-6736(11)61940-5","article-title":"Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial","volume":"379","author":"Engert","year":"2012","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.cpet.2019.03.008_bib14","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1000067","article-title":"Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma","volume":"363","author":"Engert","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"27","key":"10.1016\/j.cpet.2019.03.008_bib15","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1200\/JCO.2008.19.8820","article-title":"Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study","volume":"27","author":"Engert","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.cpet.2019.03.008_bib16","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1100340","article-title":"ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned","volume":"365","author":"Viviani","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"17","key":"10.1016\/j.cpet.2019.03.008_bib17","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"10.1016\/j.cpet.2019.03.008_bib18","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted treatment guided by interim-PET-CT scan in advanced Hodgkin's lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"10.1016\/j.cpet.2019.03.008_bib19","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1093\/jnci\/dji290","article-title":"Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma","volume":"97","author":"Travis","year":"2005","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"21","key":"10.1016\/j.cpet.2019.03.008_bib20","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1200\/JCO.2013.54.4601","article-title":"Breast cancer after chest radiation therapy for childhood cancer","volume":"32","author":"Moskowitz","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"26","key":"10.1016\/j.cpet.2019.03.008_bib21","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1200\/JCO.2008.19.9174","article-title":"Breast cancer risk in female survivors of Hodgkin's lymphoma: lower risk after smaller radiation volumes","volume":"27","author":"de Bruin","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.cpet.2019.03.008_bib22","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/j.1365-2141.2012.09211.x","article-title":"Patterns of subsequent malignancies after Hodgkin lymphoma in children and adults","volume":"158","author":"Omer","year":"2012","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.cpet.2019.03.008_bib23","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1093\/annonc\/mdl302","article-title":"Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials","volume":"17","author":"Franklin","year":"2006","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.cpet.2019.03.008_bib24","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.ijrobp.2009.01.073","article-title":"Roles of radiation dose and chemotherapy in the etiology of stomach cancer as a second malignancy","volume":"75","author":"van den Belt-Dusebout","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"27","key":"10.1016\/j.cpet.2019.03.008_bib25","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1200\/JCO.2013.50.6832","article-title":"Stomach cancer risk after treatment for Hodgkin lymphoma","volume":"31","author":"Morton","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.cpet.2019.03.008_bib26","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1200\/JCO.2001.19.6.1610","article-title":"Lung cancer after Hodgkin\u2019s disease: a nested case-control study of the relation to treatment","volume":"19","author":"Swerdlow","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"issue":"31","key":"10.1016\/j.cpet.2019.03.008_bib27","doi-asserted-by":"crossref","first-page":"4096","DOI":"10.1200\/JCO.2011.34.8268","article-title":"Second cancer risk after chemotherapy for Hodgkin's lymphoma: a collaborative British cohort study","volume":"29","author":"Swerdlow","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.cpet.2019.03.008_bib28","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S1470-2045(05)70387-9","article-title":"Lung cancer after treatment for Hodgkin's lymphoma: a systematic review","volume":"6","author":"Lorigan","year":"2005","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.cpet.2019.03.008_bib29","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1200\/JCO.2012.44.5791","article-title":"Risk of therapy-related secondary leukemia in Hodgkin lymphoma: the Stanford University experience over three generations of clinical trials","volume":"31","author":"Koontz","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.cpet.2019.03.008_bib30","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1182\/blood-2013-07-512657","article-title":"Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group","volume":"123","author":"Eichenauer","year":"2014","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.cpet.2019.03.008_bib31","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1200\/JCO.2015.63.4444","article-title":"Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma","volume":"34","author":"van Nimwegen","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"30","key":"10.1016\/j.cpet.2019.03.008_bib32","doi-asserted-by":"crossref","first-page":"7614","DOI":"10.1200\/JCO.2005.02.7243","article-title":"Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma","volume":"23","author":"Martin","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.cpet.2019.03.008_bib33","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/JCO.2012.44.3721","article-title":"Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials","volume":"31","author":"Behringer","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.cpet.2019.03.008_bib34","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/hon.802","article-title":"Fertility among female Hodgkin lymphoma survivors attempting pregnancy following ABVD chemotherapy","volume":"25","author":"Hodgson","year":"2007","journal-title":"Hematol Oncol"},{"issue":"4","key":"10.1016\/j.cpet.2019.03.008_bib35","first-page":"686","article-title":"The use of FDG-PET in the detection and management of malignant lymphoma: correlation of uptake with prognosis","volume":"32","author":"Okada","year":"1991","journal-title":"J\u00a0Nucl Med"},{"issue":"1","key":"10.1016\/j.cpet.2019.03.008_bib36","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1148\/radiology.190.1.8259386","article-title":"Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT","volume":"190","author":"Newman","year":"1994","journal-title":"Radiology"},{"issue":"7","key":"10.1016\/j.cpet.2019.03.008_bib37","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1093\/annonc\/mdi200","article-title":"Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma","volume":"16","author":"Hutchings","year":"2005","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.cpet.2019.03.008_bib38","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1182\/blood-2005-06-2252","article-title":"FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma","volume":"107","author":"Hutchings","year":"2006","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.cpet.2019.03.008_bib39","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1200\/JCO.2007.11.6525","article-title":"Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study","volume":"25","author":"Gallamini","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.cpet.2019.03.008_bib40","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.2967\/jnumed.109.073197","article-title":"18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma","volume":"51","author":"Cerci","year":"2010","journal-title":"J\u00a0Nucl Med"},{"issue":"5","key":"10.1016\/j.cpet.2019.03.008_bib41","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1200\/JCO.2006.08.2305","article-title":"Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma","volume":"25","author":"Juweid","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.cpet.2019.03.008_bib42","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1080\/10428190903040048","article-title":"Report on the first international Workshop on interim-PET-scan in lymphoma","volume":"50","author":"Meignan","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"27","key":"10.1016\/j.cpet.2019.03.008_bib43","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.cpet.2019.03.008_bib44","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1093\/annonc\/mdx097","article-title":"International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)","volume":"28","author":"Younes","year":"2017","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.cpet.2019.03.008_bib45","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.2013.51.9298","article-title":"Omitting radiotherapy in early positron emission tomography-negative stage I\/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"32","author":"Raemaekers","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"16","key":"10.1016\/j.cpet.2019.03.008_bib46","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","article-title":"Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"35","author":"Andr\u00e9","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"year":"2018","series-title":"PET-guided treatment of early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase 3 trial HD16 by the German Hodgkin study group","author":"Fuchs","key":"10.1016\/j.cpet.2019.03.008_bib47"},{"issue":"10","key":"10.1016\/j.cpet.2019.03.008_bib48","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood-2018-01-827246","article-title":"CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim-PET","volume":"132","author":"Straus","year":"2018","journal-title":"Blood"},{"issue":"Supplement_4","key":"10.1016\/j.cpet.2019.03.008_bib50","doi-asserted-by":"crossref","first-page":"iv19","DOI":"10.1093\/annonc\/mdy080","article-title":"Hodgkin lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Eichenauer","year":"2018","journal-title":"Ann Oncol"},{"issue":"32","key":"10.1016\/j.cpet.2019.03.008_bib51","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.1200\/JCO.2009.23.3239","article-title":"Randomized comparison of the Stanford V regimen and ABVD in the treatment of advanced Hodgkin's lymphoma: United Kingdom National Cancer Research Institute lymphoma group study ISRCTN 64141244","volume":"27","author":"Hoskin","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.cpet.2019.03.008_bib52","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1200\/JCO.2008.17.0910","article-title":"ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial","volume":"27","author":"Federico","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"24","key":"10.1016\/j.cpet.2019.03.008_bib53","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa022473","article-title":"Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease","volume":"348","author":"Diehl","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.cpet.2019.03.008_bib54","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1200\/JCO.2017.75.2543","article-title":"Early chemotherapy intensification with escalated BEACOPP in patients with advanced-stage Hodgkin lymphoma with a positive interim positron emission tomography\/computed tomography scan after two ABVD cycles: long-term results of the GITIL\/FIL HD 0607 trial","volume":"36","author":"Gallamini","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"17","key":"10.1016\/j.cpet.2019.03.008_bib55","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1200\/JCO.2015.63.1119","article-title":"US Intergroup trial\u00a0of response-adapted therapy for stage III to IV\u00a0Hodgkin lymphoma using early interim fluorodeoxyglucose-positron emission tomography imaging: Southwest Oncology Group S0816","volume":"34","author":"Press","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.cpet.2019.03.008_bib56","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1093\/annonc\/mdv077","article-title":"Phase II study of interim-PET-CT-guided response-adapted therapy in advanced Hodgkin's lymphoma","volume":"26","author":"Ganesan","year":"2015","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.cpet.2019.03.008_bib57","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1200\/JCO.2015.63.0699","article-title":"Interim positron emission tomography response-adapted therapy in advanced-stage Hodgkin lymphoma: final results of the phase II part of the HD0801 study","volume":"34","author":"Zinzani","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.cpet.2019.03.008_bib58","doi-asserted-by":"crossref","first-page":"7503","DOI":"10.1200\/JCO.2018.36.15_suppl.7503","article-title":"Randomized phase III study comparing an early PET driven treatment de-escalation to a not PET-monitored strategy in patients with advanced stages Hodgkin lymphoma: final analysis of the AHL2011 LYSA study","volume":"36","author":"Casasnovas","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"10114","key":"10.1016\/j.cpet.2019.03.008_bib59","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1016\/S0140-6736(17)32134-7","article-title":"PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group","volume":"390","author":"Borchmann","year":"2017","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.cpet.2019.03.008_bib60","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2967\/jnumed.112.110890","article-title":"International validation study for interim-PET in ABVD-treated, advanced-stage Hodgkin lymphoma: interpretation criteria and concordance rate among reviewers","volume":"54","author":"Biggi","year":"2013","journal-title":"J\u00a0Nucl Med"},{"year":"2018","series-title":"Long-term follow-up of SWOG S0816: response-adapted therapy for stage III\/IV Hodgkin lymphoma demonstrates limitations of PET-adapted approach","author":"Stephens","key":"10.1016\/j.cpet.2019.03.008_bib61"},{"issue":"3","key":"10.1016\/j.cpet.2019.03.008_bib62","doi-asserted-by":"crossref","first-page":"e0149072","DOI":"10.1371\/journal.pone.0149072","article-title":"Inter-reader reliability of early FDG-PET\/CT response assessment using the Deauville scale after 2 cycles of intensive chemotherapy (OEPA) in Hodgkin's lymphoma","volume":"11","author":"Kluge","year":"2016","journal-title":"PLoS One"},{"issue":"18","key":"10.1016\/j.cpet.2019.03.008_bib63","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1200\/JCO.2003.07.131","article-title":"Long-term cause-specific mortality of patients treated for Hodgkin\u2019s disease","volume":"21","author":"Aleman","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"issue":"13","key":"10.1016\/j.cpet.2019.03.008_bib64","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1093\/jnci\/95.13.971","article-title":"Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease","volume":"95","author":"van Leeuwen","year":"2003","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"8","key":"10.1016\/j.cpet.2019.03.008_bib65","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1080\/10428190802140873","article-title":"Cardiac morbidity following modern treatment for Hodgkin lymphoma: supra-additive cardiotoxicity of doxorubicin and radiation therapy","volume":"49","author":"Myrehaug","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"20","key":"10.1016\/j.cpet.2019.03.008_bib66","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1200\/JCO.2009.26.0323","article-title":"Consolidation radiotherapy in patients with advanced Hodgkin's lymphoma: survival data from the UKLG LY09 randomized controlled trial (ISRCTN97144519)","volume":"28","author":"Johnson","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"24","key":"10.1016\/j.cpet.2019.03.008_bib67","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1056\/NEJMoa022628","article-title":"Involved-field radiotherapy for advanced Hodgkin's lymphoma","volume":"348","author":"Aleman","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.cpet.2019.03.008_bib68","first-page":"2246","article-title":"Comparison of chemotherapy to radiotherapy as consolidation of complete or good partial response after six cycles of chemotherapy for patients with advanced Hodgkin's disease: results of the groupe d\u2018\u00e9tudes des lymphomes de l\u2019Adulte H89 trial","volume":"95","author":"Ferme","year":"2000","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.cpet.2019.03.008_bib69","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1093\/oxfordjournals.annonc.a059357","article-title":"Further chemotherapy versus low-dose involved-field radiotherapy as consolidation of complete remission after six cycles of alternating chemotherapy in patients with advance Hodgkin\u2019s disease. German Hodgkin Study Group (GHSG)","volume":"6","author":"Diehl","year":"1995","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.cpet.2019.03.008_bib70","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1080\/10428190903161075","article-title":"Radiation therapy compared with chemotherapy for consolidation of chemotherapy-induced remission of advanced Hodgkin lymphoma: a study by the Eastern Co-operative Oncology Group (E1476) with\u00a0>20 years follow-up","volume":"50","author":"Wiernik","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.cpet.2019.03.008_bib71","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1470-2045(15)70013-6","article-title":"PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study","volume":"16","author":"Moskowitz","year":"2015","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.cpet.2019.03.008_bib72","first-page":"331","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma","volume":"378","author":"Connors","year":"2018"},{"year":"2017","series-title":"Nivolumab treatment beyond investigator-assessed progression: outcomes in patients with relapsed\/refractory classical Hodgkin lymphoma from the phase 2 checkmate 205 study","author":"Cohen","key":"10.1016\/j.cpet.2019.03.008_bib73"},{"issue":"6","key":"10.1016\/j.cpet.2019.03.008_bib74","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/ejh.12791","article-title":"Controversies on the prognostic value of interim FDG-PET in advanced-stage Hodgkin lymphoma","volume":"97","author":"Adams","year":"2016","journal-title":"Eur J Haematol"},{"issue":"2","key":"10.1016\/j.cpet.2019.03.008_bib75","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1148\/rg.242025724","article-title":"An introduction to PET-CT imaging","volume":"24","author":"Kapoor","year":"2004","journal-title":"Radiographics"},{"issue":"2","key":"10.1016\/j.cpet.2019.03.008_bib76","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1600-0609.2006.00675.x","article-title":"Effect of drug-induced cytotoxicity on glucose uptake in Hodgkin's lymphoma cells","volume":"77","author":"Banning","year":"2006","journal-title":"Eur J Haematol"},{"issue":"9","key":"10.1016\/j.cpet.2019.03.008_bib77","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1007\/s00259-014-2783-x","article-title":"Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma","volume":"41","author":"Kanoun","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"20","key":"10.1016\/j.cpet.2019.03.008_bib78","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1182\/blood-2017-06-788877","article-title":"Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma","volume":"130","author":"Moskowitz","year":"2017","journal-title":"Blood"}],"container-title":["PET Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556859819300240?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556859819300240?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:06:27Z","timestamp":1761563187000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556859819300240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":76,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S1556859819300240"],"URL":"https:\/\/doi.org\/10.1016\/j.cpet.2019.03.008","relation":{},"ISSN":["1556-8598"],"issn-type":[{"type":"print","value":"1556-8598"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Response-Adapted Treatment Strategies in Hodgkin Lymphoma Using PET Imaging","name":"articletitle","label":"Article Title"},{"value":"PET Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpet.2019.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}